CorMedix Inc. (CRMD)
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
CorMedix: Exceeding Expectations
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Gregory Renza – RBC Capital Roana Ruiz – Leerink Partners Leszek Sulewski – Truist Securities Serge Belanger – Needham & Company Operator Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode.
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago.
CorMedix: A Fair-Priced Biotech Company With A Bright Future
CorMedix Inc.'s DefenCath, FDA-approved in Q4 2023, effectively prevents catheter-related bloodstream infections in hemodialysis patients, showing 71% efficacy compared to competitors. Despite recent profitability and strong market potential, the stock price has increased post-FDA approval, making it appropriately priced for its risk level. Key risks include adoption speed, supply chain scalability, and regulatory changes; maintaining relationships with major dialysis operators is crucial.
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Jeevan Larson - Truist Securities John Todaro - Needham & Company Operator Good day and welcome to the CorMedix Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. All participants will be in listen-only mode.
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.26 per share a year ago.
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
CorMedix Inc. CRMD will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
